摘要分化型甲状腺癌（DTC）是最常见的内分泌系统恶性肿瘤，早期易发生淋巴结转移。 131I全身显像联合SPECT/CT（简称 131I SPECT/CT）常可发现残留和（或）漏诊的淋巴结转移灶，可能会改变患者的术后再分期及危险度分层，从而影响后续的手术或 131I治疗的方式选择。 131I治疗是DTC术后颈部淋巴结转移的有效治疗方法之一，而 131I SPECT/CT可以诊断淋巴结转移灶。笔者对 131I SPECT/CT在DTC术后淋巴结转移的诊断及治疗中的应用价值进行综述。

abstractsDifferentiated thyroid cancer (DTC) is the most common endocrine malignancy, which is prone to lymph node metastasis in the early stage. 131I whole body scan combining with SPECT/CT (called 131I SPECT/CT for short) can often detect residual and/or missed lymph node metastasis, which may change the postoperative staging and risk stratification of patients, affect subsequent surgical or 131I therapy options. 131I therapy is one of the effect methods for the treatment of postoperative cervical lymph node metastasis in DTC. Metastatic lymph nodes can be diagnosed by 131I SPECT/CT. This article reviews the application value of 131I SPECT/CT in the diagnosis and treatment of postoperative lymph node metastasis in patients with differentiated thyroid cancer.